US Stock MarketDetailed Quotes
IVA Inventiva
- 2.320
- +0.045+1.98%
Trading Dec 19 09:32 ET
202.02MMarket Cap-1.09P/E (TTM)
2.320High2.290Low617Volume2.220Open2.275Pre Close1.42KTurnover0.00%Turnover RatioLossP/E (Static)87.08MShares4.75052wk High-2.47P/B57.22MFloat Cap1.53052wk Low--Dividend TTM24.66MShs Float19.064Historical High--Div YieldTTM1.32%Amplitude1.530Historical Low2.305Avg Price1Lot Size
Inventiva Stock Forum
Sign in to post a comment
$Inventiva (IVA.US)$
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Monday, 16th December at 2:30 am
◦ Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.
◦ Proceeds from the completed first tranche to be primarily used to advance Inventiva's ...
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
Monday, 16th December at 2:30 am
◦ Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.
◦ Proceeds from the completed first tranche to be primarily used to advance Inventiva's ...
1
$Inventiva (IVA.US)$ Inventiva Announces The Recommendation Of The Fifth DMC Of The NATiV3 Phase 3 Clinical Trial With Lanifibranor In Patients With MASH
Benzinga· 3 mins ago
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts,...
Benzinga· 3 mins ago
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts,...
$Inventiva (IVA.US)$https://www.moomoo.com/news/notice/301091081?ns_stock_id=79237851862280&client_hour_clock=24&main_broker=WwogIDEwMDgKXQ%3D%3D&sg_cid=103382313&skintype=1&jp_cid=103382313&futusource=news_stock_stockpagenews&level=0&global_content=%7B%22promote_content%22%3A%22mm%3Anotice%3A301091081%22%2C%22invite%22%3A103382313%7D&data_ticket=1725015159622121
Big buyout of the stocks?
Big buyout of the stocks?
$Semilux (SELX.US)$ $Bright Minds Biosciences (DRUG.US)$ $Gritstone Bio (GRTS.US)$ $B. Riley Financial (RILY.US)$ $Eco Wave Power (WAVE.US)$ $Rani Therapeutics (RANI.US)$ $Inventiva (IVA.US)$ $Expion360 (XPON.US)$ $Longboard Pharmaceuticals(Delisted) (LBPH.US)$ $Verb Technology (VERB.US)$ $Tevogen Bio Holdings (TVGN.US)$
7
2
$Destiny Tech100 (DXYZ.US)$ $Vanda Pharmaceuticals (VNDA.US)$ $In8bio (INAB.US)$ $Rani Therapeutics (RANI.US)$ $Jasper Therapeutics (JSPR.US)$ $B Riley Financial Inc 7.5% Sr Nts 31/05/2027 Usd25 (RILYZ.US)$ $B. Riley Financial Inc (RILYP.US)$ $B Riley Financial Inc 6.375% Senior Notes Due 2025 (RILYM.US)$ $B. Riley Financial (RILY.US)$ $Longboard Pharmaceuticals(Delisted) (LBPH.US)$ $Expion360 (XPON.US)$ $Inventiva (IVA.US)$ $Tevogen Bio Holdings (TVGN.US)$
1
$Inventiva (IVA.US)$ Inventiva Gets New Funding for Late-stage Trial of Fatty Liver Disease Treatment
MT Newswires· 5 mins ago
Inventiva (IVA.PA) secured new financing primarily earmarked for the phase 3 trial of its lanifibranor treatment for metabolic dysfunction-associated steatohepatitis, a fatty liver disease and its subsequent marketing approval and commercialization.
The clinical-stage biopharmaceutical company secured an immediate financing of 94.1 million euros worth of shares and ...
MT Newswires· 5 mins ago
Inventiva (IVA.PA) secured new financing primarily earmarked for the phase 3 trial of its lanifibranor treatment for metabolic dysfunction-associated steatohepatitis, a fatty liver disease and its subsequent marketing approval and commercialization.
The clinical-stage biopharmaceutical company secured an immediate financing of 94.1 million euros worth of shares and ...
6
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Inventiva (IVA.US)$ Japanese Patent Office Approves Inventiva's Patent For Use Of Lanifibranor In Treating Cirrhosis, Strengthening IP For MASH/NASH Indications; Patent Valid Until November 2039
2
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
70980870 : thanks